Heather A. Hirsch, Ph.D.
Affiliations: | 2003 | Michigan State University, East Lansing, MI |
Area:
Molecular BiologyGoogle:
"Heather Hirsch"Parents
Sign in to add mentor| R. William Henry | grad student | 2003 | Michigan State | |
| (Regulation of U6 small nuclear RNA transcription by the retinoblastoma tumor suppressor protein.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hirsch HA, Reeves J, Zi T, et al. (2017) Biomarker-driven indication selection in JTX-2011 ICONIC clinical trial. Journal of Clinical Oncology. 35: 11602-11602 |
| Haines BB, Javaid S, Cui L, et al. (2017) Abstract 4714: Blockade of LAG-3 amplifies immune activation signatures and augments curative antitumor responses to anti-PD-1 therapy in immune competent mouse models of cancer Cancer Research. 77: 4714-4714 |
| Hirsch H, Mangadu R, Cai M, et al. (2016) Abstract B114: Evaluation of the antitumor activity and molecular characterization of mouse syngeneic tumor models in response to anti-PD-1 treatment as a single agent and in combination with approved agents Cancer Immunology Research. 4 |
| Deshpande A, Growdon WB, Hirsch H, et al. (2016) Abstract A052: Characterization of immune regulatory molecules B7-H4, PD-L1, and ICOS in micro-satellite stable (MSS) and micro-satellite instable (MSI) endometrial tumors Cancer Immunology Research. 4 |
| Pinheiro EM, Hinton M, Mangadu R, et al. (2016) Abstract 543: Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab Cancer Research. 76: 543-543 |
| Pinheiro EM, Mangadu R, Phan UT, et al. (2015) Abstract 269: Evaluation of the antitumor activity of anti-PD-1 immunotherapy as a single agent and in combination with approved agents in preclinical tumor models Cancer Research. 75: 269-269 |
| Hirsch HA, Pinheiro EM, Cai M, et al. (2015) Abstract 1328: Molecular characterization of mouse syngeneic tumor models in response to treatment with anti-PD-1 immunotherapy Cancer Research. 75: 1328-1328 |
| Ayers MD, Nebozhyn M, Hirsch HA, et al. (2015) Abstract 1307: Assessment of gene expression in peripheral blood from patients with advanced melanoma using RNA-seq before and after treatment with anti-PD-1 therapy with pembrolizumab (MK-3475) Cancer Research. 75: 1307-1307 |
| Muvaffak A, Pan Q, Yan H, et al. (2014) Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Molecular Cancer Research : McR. 12: 1055-66 |
| Hatch H, Booher R, Perera S, et al. (2013) Abstract 698: MCL1 dependent cells are sensitive to the CDK inhibitor Dinaciclib. Cancer Research. 73: 698-698 |